<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Database (Oxford)</journal-id>
    <journal-id journal-id-type="iso-abbrev">Database (Oxford)</journal-id>
    <journal-id journal-id-type="publisher-id">databa</journal-id>
    <journal-title-group>
      <journal-title>Database: The Journal of Biological Databases and Curation</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1758-0463</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
      <publisher-loc>UK</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9419874</article-id>
    <article-id pub-id-type="doi">10.1093/database/baac075</article-id>
    <article-id pub-id-type="publisher-id">baac075</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Database Tool</subject>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00960</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>SLOAD: a comprehensive database of cancer-specific synthetic lethal interactions for precision cancer therapy via multi-omics analysis</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Guo</surname>
          <given-names>Li</given-names>
        </name>
        <aff><institution content-type="department">Department of Bioinformatics, Smart Health Big Data Analysis and Location Services Engineering Lab of Jiangsu Province, School of Geographic and Biologic Information, Nanjing University of Posts and Telecommunications</institution>, No. 9, Wenyuan Road, Qixia District, Nanjing, Jiangsu 210023, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Dou</surname>
          <given-names>Yuyang</given-names>
        </name>
        <aff><institution content-type="department">Department of Bioinformatics, Smart Health Big Data Analysis and Location Services Engineering Lab of Jiangsu Province, School of Geographic and Biologic Information, Nanjing University of Posts and Telecommunications</institution>, No. 9, Wenyuan Road, Qixia District, Nanjing, Jiangsu 210023, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Xia</surname>
          <given-names>Daoliang</given-names>
        </name>
        <aff><institution content-type="department">Department of Bioinformatics, Smart Health Big Data Analysis and Location Services Engineering Lab of Jiangsu Province, School of Geographic and Biologic Information, Nanjing University of Posts and Telecommunications</institution>, No. 9, Wenyuan Road, Qixia District, Nanjing, Jiangsu 210023, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yin</surname>
          <given-names>Zibo</given-names>
        </name>
        <aff><institution content-type="department">Department of Bioinformatics, Smart Health Big Data Analysis and Location Services Engineering Lab of Jiangsu Province, School of Geographic and Biologic Information, Nanjing University of Posts and Telecommunications</institution>, No. 9, Wenyuan Road, Qixia District, Nanjing, Jiangsu 210023, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Xiang</surname>
          <given-names>Yangyang</given-names>
        </name>
        <aff><institution content-type="department">Department of Bioinformatics, Smart Health Big Data Analysis and Location Services Engineering Lab of Jiangsu Province, School of Geographic and Biologic Information, Nanjing University of Posts and Telecommunications</institution>, No. 9, Wenyuan Road, Qixia District, Nanjing, Jiangsu 210023, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Luo</surname>
          <given-names>Lulu</given-names>
        </name>
        <aff><institution content-type="department">Jiangsu Key Laboratory for Molecular and Medical Biotechnology, School of Life Science, Nanjing Normal University</institution>, No. 1, Wenyuan Road, Qixia District, Nanjing, Jiangsu 210023, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Yuting</given-names>
        </name>
        <aff><institution content-type="department">Department of Bioinformatics, Smart Health Big Data Analysis and Location Services Engineering Lab of Jiangsu Province, School of Geographic and Biologic Information, Nanjing University of Posts and Telecommunications</institution>, No. 9, Wenyuan Road, Qixia District, Nanjing, Jiangsu 210023, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Jun</given-names>
        </name>
        <aff><institution content-type="department">Department of Bioinformatics, Smart Health Big Data Analysis and Location Services Engineering Lab of Jiangsu Province, School of Geographic and Biologic Information, Nanjing University of Posts and Telecommunications</institution>, No. 9, Wenyuan Road, Qixia District, Nanjing, Jiangsu 210023, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6421-0010</contrib-id>
        <name>
          <surname>Liang</surname>
          <given-names>Tingming</given-names>
        </name>
        <!--tmliang@njnu.edu.cn-->
        <xref rid="COR0001" ref-type="corresp"/>
        <aff><institution content-type="department">Jiangsu Key Laboratory for Molecular and Medical Biotechnology, School of Life Science, Nanjing Normal University</institution>, No. 1, Wenyuan Road, Qixia District, Nanjing, Jiangsu 210023, <country country="CN">China</country></aff>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR0001">*Corresponding author: Tel: +86 02585891050; Fax: +86 02585891050; Email: <email xlink:href="tmliang@njnu.edu.cn">tmliang@njnu.edu.cn</email></corresp>
      <p>Li Guo is an associate professor at the School of Geographic and Biologic Information, Nanjing University of Posts and Telecommunications, China. Her research interests include bioinformatics and computational biology.</p>
      <p>Yuyang Dou is a master’s student at the School of Geographic and Biologic Information, Nanjing University of Posts and Telecommunications, China. His research interests include bioinformatics and computational biology.</p>
      <p>Daoliang Xia is a master’s student at the School of Geographic and Biologic Information, Nanjing University of Posts and Telecommunications, China. His research interests include bioinformatics and computational biology.</p>
      <p>Zibo Yin is a master’s student at the School of Geographic and Biologic Information, Nanjing University of Posts and Telecommunications, China. His research interests include bioinformatics and computational biology.</p>
      <p>Yangyang Xiang is a master’s student at the School of Geographic and Biologic Information, Nanjing University of Posts and Telecommunications, China. Her research interests include bioinformatics and computational biology.</p>
      <p>Lulu Luo is a master’s student at the School of Life Science, Nanjing Normal University, China. Her research interests include cancer molecular biology.</p>
      <p>Yuting Zhang is a master’s candidate at the School of Geographic and Biologic Information, Nanjing University of Posts and Telecommunications, China. Her research interests include bioinformatics and computational biology.</p>
      <p>Jun Wang is a professor at the School of Geographic and Biologic Information, Nanjing University of Posts and Telecommunications, China. His research interests include bioinformatics and computational biology.</p>
      <p>Tingming Liang is an associate professor at the School of Life Science, Nanjing Normal University, China. His research interests include cancer molecular biology and bioinformatics.</p>
    </author-notes>
    <pub-date pub-type="collection">
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2022-08-27">
      <day>27</day>
      <month>8</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>27</day>
      <month>8</month>
      <year>2022</year>
    </pub-date>
    <volume>2022</volume>
    <elocation-id>baac075</elocation-id>
    <history>
      <date date-type="received">
        <day>15</day>
        <month>6</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>27</day>
        <month>7</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>20</day>
        <month>8</month>
        <year>2022</year>
      </date>
      <date date-type="editorial-decision">
        <day>15</day>
        <month>8</month>
        <year>2022</year>
      </date>
      <date date-type="corrected-typeset">
        <day>27</day>
        <month>8</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2022. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2022</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="baac075.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Synthetic lethality has been widely concerned because of its potential role in cancer treatment, which can be harnessed to selectively kill cancer cells via identifying inactive genes in a specific cancer type and further targeting the corresponding synthetic lethal partners. Herein, to obtain cancer-specific synthetic lethal interactions, we aimed to predict genetic interactions via a pan-cancer analysis from multiple molecular levels using random forest and then develop a user-friendly database. First, based on collected public gene pairs with synthetic lethal interactions, candidate gene pairs were analyzed via integrating multi-omics data, mainly including DNA mutation, copy number variation, methylation and mRNA expression data. Then, integrated features were used to predict cancer-specific synthetic lethal interactions using random forest. Finally, SLOAD (<ext-link xlink:href="http://www.tmliang.cn/SLOAD" ext-link-type="uri">http://www.tmliang.cn/SLOAD</ext-link>) was constructed via integrating these findings, which was a user-friendly database for data searching, browsing, downloading and analyzing. These results can provide candidate cancer-specific synthetic lethal interactions, which will contribute to drug designing in cancer treatment that can promote therapy strategies based on the principle of synthetic lethality.</p>
      <p>
        <bold>Database URL</bold>
        <ext-link xlink:href="http://www.tmliang.cn/SLOAD/" ext-link-type="uri">http://www.tmliang.cn/SLOAD/</ext-link>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>the key project of social development in Jiangsu Province</institution>
          </institution-wrap>
        </funding-source>
        <award-id>BE2022799</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Qinglan Project</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>NUPTSF</institution>
          </institution-wrap>
        </funding-source>
        <award-id>NY220041</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>61771251</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>62171236</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>the Priority Academic Program Development of Jiangsu Higher Education Institution (PAPD)</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>the key projects of Natural Science Research in Universities of Jiangsu Province</institution>
          </institution-wrap>
        </funding-source>
        <award-id>22KJA180006</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>State Key Laboratory of Bioelectronics, Southeast University</institution>
          </institution-wrap>
        </funding-source>
        <award-id>SKLB2022-K03</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="8"/>
    </counts>
  </article-meta>
</front>
<body>
  <boxed-text id="BX1" position="float">
    <label>Highlights</label>
    <list list-type="bullet">
      <list-item>
        <p>Integrated features from multi-omics data were firstly collected.</p>
      </list-item>
      <list-item>
        <p>Cancer-specific synthetic lethal interactions were then predicted using random forest.</p>
      </list-item>
      <list-item>
        <p>SLOAD, a user-friendly database, was constructed based on predicted results.</p>
      </list-item>
    </list>
  </boxed-text>
  <sec id="s3">
    <title>Introduction</title>
    <p>Accumulating evidence has revealed that synthetic lethality (SL) has been an emerging and important therapeutic strategy for cancer treatment by exploiting potential interactions between driving mutations and specific drug targets. A synthetic lethal interaction occurs when the perturbation of two nonessential genes with SL is lethal (<xref rid="R1" ref-type="bibr">1</xref>), which can be harnessed to selectively treat cancer via characterizing inactive genes and then targeting the corresponding synthetic lethal partners (<xref rid="R2" ref-type="bibr">2</xref>). These genetic interactions between tumor suppressor genes and other genes can simultaneously disrupt both gene functions, which further cause rapid and selective cell death (<xref rid="R3" ref-type="bibr">3</xref>). The strategy of SL provides an opportunity for mutations caused by a loss of function without available targeted therapies. The concept of ‘synthetic lethality’ has been widely concerned in cancer treatment, and treatment of cancer-deficient tumors with PARP inhibitors always selectively kills the cancer cells in some cancers (<xref rid="R4" ref-type="bibr">4–9</xref>). Thus, this phenomenon caused by synthetic lethal interactions provides a possibility to develop selective anticancer drugs by targeting a gene whose partner is inactive only in tumor cells (<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R10" ref-type="bibr">10</xref>).</p>
    <p>Based on the potential application of SL in cancer treatment, it is quite crucial to obtain a data set containing synthetic lethal interactions with higher confidence that can provide data references for precision cancer therapy. In recent years, many studies attempted to find synthetic lethal interactions, especially potential interactions in some model organisms (<xref rid="R11" ref-type="bibr">11–14</xref>) and humans (<xref rid="R2" ref-type="bibr">2</xref>, <xref rid="R15" ref-type="bibr">15–21</xref>). According to phylogenetic conservation, some human synthetic lethal interactions have been computationally inferred from yeast (<xref rid="R22" ref-type="bibr">22</xref>) and collected via using metabolic models and evolutionary characteristics of metabolic genes (<xref rid="R23" ref-type="bibr">23–25</xref>). These predicted interactions provide many references for human genetic interactions, but SL in humans is far more complex than we initially thought. Currently, many candidate interactions have been reported based on diverse approaches or algorithms (<xref rid="R26" ref-type="bibr">26–29</xref>), even via integrating multiple molecular levels, and these studies largely contribute to revealing the synthetic lethal interactions and promoting their potential application in cancer precision treatment. However, it is not sufficient to further understand these interactions, particularly in diverse cancer types. In-depth understanding of cancer-specific synthetic lethal interactions will contribute to their application in cancer treatment, which will provide an important reference for exploring cancer-specific susceptibilities and further treatments.</p>
    <p>Herein, toward the realization of the potential application of the concept of SL in cancer treatment, we aimed to predict and analyze candidate cancer-specific interactions through an integrative multi-omics analysis (<xref rid="F1" ref-type="fig">Figure 1</xref>). Firstly, currently reported candidate genetic interactions were collected; an integrative analysis of multi-omics data analysis was performed to screen molecular features, mainly including DNA level [DNA mutation, copy number variation (CNV) and methylation] and mRNA expression level. Secondly, cancer-specific synthetic lethal interactions in 31 cancers were predicted using random forest (RF). Finally, we constructed a user-friendly and open-access database containing cancer-specific gene pairs and primary analysis. Our study may provide cancer-specific data sources and drug targets for further validation and clinical application in precision cancer therapy.</p>
    <fig position="float" id="F1" fig-type="figure">
      <label>Figure 1.</label>
      <caption>
        <p>The main flow chart of SLOAD.</p>
      </caption>
      <graphic xlink:href="baac075f1" position="float"/>
      <attrib>* indicates 2395 validated gene pairs without SL.</attrib>
    </fig>
  </sec>
  <sec id="s4">
    <title>Materials and methods</title>
    <sec id="s4-s1">
      <title>Data resource and data processing</title>
      <p>In order to obtain cancer-specific synthetic lethal interactions, candidate genetic interactions were firstly collected to perform further analysis (<xref rid="F1" ref-type="fig">Figure 1</xref>). A total of predicted 142 602 candidate synthetic lethal interactions were mainly obtained from DAISY (<xref rid="R19" ref-type="bibr">19</xref>) and MiSL (<xref rid="R18" ref-type="bibr">18</xref>) algorithms after removing redundancy. Further, 6518 pairs of experimentally validated synthetic lethal interactions were collected according to published references, including 6033 pairs from Lee <italic toggle="yes">et al.</italic> (<xref rid="R30" ref-type="bibr">30</xref>); 162 pairs validated in Hela, A549 and 293 T cell lines (<xref rid="R31" ref-type="bibr">31</xref>); 46 pairs from Syn-lethality database (<xref rid="R21" ref-type="bibr">21</xref>); 177 pairs from Srivas <italic toggle="yes">et al.</italic> (<xref rid="R32" ref-type="bibr">32</xref>) and 100 reported gene pairs from published literature (<xref rid="s7" ref-type="sec">Table S1</xref>). Simultaneously, another 2467 pairs without SL in Hela, A549 and 293 T cell lines were also collected (<xref rid="R31" ref-type="bibr">31</xref>). Of these, 177 pairs were removed due to contradictory results in different analyses, 554 were removed due to repeated results and a total of 5859 experimentally validated gene pairs and 2395 validated pairs without SL were finally collected.</p>
      <p>Multi-omics data, mainly including DNA mutation, CNV, methylation and mRNA expression data in 33 cancer types, were obtained from The Cancer Genome Atlas (TCGA) Web site using the TCGAbiolinks package (<xref rid="R33" ref-type="bibr">33</xref>). Genes were removed from further analysis if they were not detected in more than 10<italic toggle="yes">n</italic>% total samples according to mRNA expression level (reads per kilobase per million mapped reads, RPKM value), mutation, CNV and methylation (beta-value). Of these, <italic toggle="yes">n</italic> was defined as 7 according to a linear relationship of distributions of the median and average values to ensure that abnormal data had the least effect on the total data distribution. Furthermore, normalized normal data in 27 cancers from Genotype-Tissue Expression (GTEx) database (<xref rid="R34" ref-type="bibr">34</xref>, <xref rid="R35" ref-type="bibr">35</xref>) were also downloaded to involve in differential expression analysis (<xref rid="s7" ref-type="sec">Table S2</xref>).</p>
    </sec>
    <sec id="s4-s2">
      <title>Estimation of features from diverse molecular levels</title>
      <p>For gene A:gene B pair, mutation coverage was estimated at mutation level (<xref rid="R36" ref-type="bibr">36</xref>) [<xref rid="M0001" ref-type="disp-formula">Equation (1)</xref>]:
<disp-formula id="M0001"><label>(1)</label><tex-math notation="LaTeX" id="M0001-Latex">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$${\rm Score}_{MC} = \frac{A+B-C}{D} $$\end{document}</tex-math></disp-formula></p>
      <p>where <italic toggle="yes">A</italic> was the sample size with gene A mutation, <italic toggle="yes">B</italic> was the sample size with gene B mutation, <italic toggle="yes">C</italic> was the sample size with both genes mutated and <italic toggle="yes">D</italic> was the total sample size in a specific cancer type. At the mRNA level, dysregulated mRNA expression profiles were firstly analyzed using edgeR package (<xref rid="R37" ref-type="bibr">37</xref>), and only 31 cancer types were involved in differential expression analysis (mesothelioma and uveal melanoma were not involved in analysis due to lack of normal samples). The value of the mRNA expression feature was estimated using the following formula [<xref rid="M0002" ref-type="disp-formula">Equation (2)</xref>]:
<disp-formula id="M0002"><label>(2)</label><tex-math notation="LaTeX" id="M0002-Latex">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$${\rm Score}_{\rm mRNA} = \sqrt{\left(-\textit{log}_{10} p_{\text{adj}}\right)^{2} + \left(\textit{log}_{2} \text{FC}\right)^{2}} $$\end{document}</tex-math></disp-formula></p>
      <p>where fold change (FC) and <italic toggle="yes">p</italic><sub>adj</sub> (adjusted <italic toggle="yes">P</italic> value) were obtained from differential expression analysis using EdgeR (<xref rid="R37" ref-type="bibr">37</xref>). Further, the average beta-value of each gene was calculated, and the value of methylation feature was estimated at the DNA methylation level [<xref rid="M0003" ref-type="disp-formula">Equation (3)</xref>]:
<disp-formula id="M0003"><label>(3)</label><tex-math notation="LaTeX" id="M0003-Latex">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$${\rm Score}_{\rm methylation} = \frac{{\rm BetaValue}_{A} + {\rm BetaValue}_{B}}{2}$$\end{document}</tex-math></disp-formula></p>
      <p>where BetaValue<italic toggle="yes"><sub>A</sub></italic> and BetaValue<italic toggle="yes"><sub>B</sub></italic> were beta-values of paired gene A and gene B, respectively. Finally, the feature was estimated at levels of gene amplification and deletion [<xref rid="M0004" ref-type="disp-formula">Equation (4)</xref>]:
<disp-formula id="M0004"><label>(4)</label><tex-math notation="LaTeX" id="M0004-Latex">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$${\rm Score}_{\rm CNV} = {{{\bf{\it{A}}} + {\bf{\it{B}}}} \over {\bf{\it{C}}}}\; \times \;{1 \over 2}$$\end{document}</tex-math></disp-formula></p>
      <p>where <italic toggle="yes">A</italic> was the sample size of gene A with significant amplification (&gt;1) or significant deletion (&lt;−1), <italic toggle="yes">B</italic> was the sample size of gene B with significant amplification or deletion and <italic toggle="yes">C</italic> was the total sample size.</p>
    </sec>
    <sec id="s4-s3">
      <title>Prediction of cancer-specific synthetic lethal interactions</title>
      <p>RF was used to predict cancer-specific synthetic lethal interactions using randomForest R package (<xref rid="R38" ref-type="bibr">38</xref>). The cancer-specific training set was firstly constructed based on the correlations of DNA mutation, mRNA expression and CNV levels. Specifically, if one gene was detected mutation, its partner would have a higher expression level and would be amplified more frequently or deleted less frequently harboring the mutation (<xref rid="R18" ref-type="bibr">18</xref>, <xref rid="R31" ref-type="bibr">31</xref>). Then, based on the potential relationships of different molecular levels, experimentally validated gene pairs were defined as positive and negative samples. Moreover, some cancers were found with sample imbalance that might influence effective prediction, and a negative sampling strategy was used to improve recall (more than 70% after treatment in all cancer types). The model performance was estimated using a 10-fold cross-validation method, and the model was also evaluated using accuracy, recall and a receive operating characteristic curve to calculate the area under the curve (AUC). Then, for each cancer type, the whole data set was used to construct the classifier. The primary predicted cancer-specific synthetic lethal interactions were collected by classifying the candidate interactions, and further filtering was performed based on strategies mentioned above to ensure the correctness.</p>
      <p>Finally, according to predicted cancer-specific results, a user-friendly SLOAD database for data searching, browsing, downloading and analyzing was constructed.</p>
    </sec>
  </sec>
  <sec id="s5">
    <title>Results</title>
    <sec id="s5-s1">
      <title>The overall predicted cancer-specific synthetic lethal interactions</title>
      <p>The prediction performances using RF were better than our previous study using decision tree in cancers (<xref rid="F2" ref-type="fig">Figure 2A</xref>). Both the accuracy and AUC values showed a significant difference between the two algorithms, indicating better prediction results using RF method (<xref rid="F2" ref-type="fig">Figure 2B</xref>). Integrated feature of multi-omics data had a higher AUC value than the feature at the single molecular level (<xref rid="F2" ref-type="fig">Figure 2C</xref>), despite different cancer types showing varied results. Of these, DNA mutation had a larger contribution to prediction accuracy, while methylation had less effect on the prediction of SL than other molecular levels. These results indicated that integrative analysis of multi-omics data was the best choice to predict cancer-specific synthetic lethal interactions, which provided more data reference for further discussing the potential molecular mechanisms associated with SL.</p>
      <fig position="float" id="F2" fig-type="figure">
        <label>Figure 2.</label>
        <caption>
          <p>Primary analysis of predicted cancer-specific synthetic lethal interactions.</p>
        </caption>
        <graphic xlink:href="baac075f2" position="float"/>
        <attrib>(A) The distributions of AUC values based on different algorithms (decision tree and RF). (B) Significant difference of accuracy and AUC can be detected between different algorithms DT shows decision tree algorithm, and RF shows random forest algorithm. (C) The distributions of AUC values based on different feature selections across cancers. Feature selections mainly include feature of single molecular level and integrated features from multi-omics data. (D) The distribution of interacted numbers based on all the predicted synthetic lethal interactions, and the pie distribution is also presented. (E) The number distributions of synthetic lethal interactions shared by cancers. Many of these gene pairs are shared by multiple cancers, and several gene pairs shared by more than 28 cancers are highlighted. The below picture shows that diverse cancers are detected with different numbers of genetic interactions. (F) An example of an interaction network shows genetic interactions between genes. Each circle indicates a pie distribution of expression patterns in 31 cancers.</attrib>
      </fig>
      <p>Herein, a total of 139 035 gene pairs were collected from 31 cancer types, containing 10 377 genes. Of these, most genes (75.78%) were detected in more than one interaction with other genes (<xref rid="F2" ref-type="fig">Figure 2D</xref>). Genes with one interaction were the most popular (24.22%), followed by two interactions (10.97%), indicating that many genes were only found in rare synthetic lethal interactions, while some specific genes may have widespread interactions with other genes. For example, KRAS, PIK3CA and CSMD3 were found more than 1000 interactions. Indeed, KRAS, an oncogenic gene, has been validated by synthetic lethal interaction with other genes, and the determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells may contribute to revealing novel therapeutic targeting strategies (<xref rid="R39" ref-type="bibr">39–41</xref>). These multiple interactions may implicate their important roles in tumorigenesis and further clinical application in cancer treatment based on the concept of SL.</p>
      <p>Numbers of predicted gene pairs were different in 31 cancer types, and many synthetic lethal interactions were detected in multiple cancers, especially shared by 7–14 cancers (<xref rid="F2" ref-type="fig">Figure 2E</xref>). Some gene pairs were shared by more than 20 cancers, such as TP53:ATR and CHEK2:TTN were detected in 29 cancer types. The genetic interactions among genes were complex (<xref rid="F2" ref-type="fig">Figure 2F</xref>), especially for those pairs shared by multiple cancers. Some genes were involved in dynamic expression patterns across cancers, implicating the potential biological roles associated with specific cancers. These cancer-specific synthetic lethal interactions can provide candidate drug targets for precision treatment.</p>
    </sec>
    <sec id="s5-s2">
      <title>Web interface</title>
      <p>SLOAD (<ext-link xlink:href="http://www.tmliang.cn/SLOAD" ext-link-type="uri">http://www.tmliang.cn/SLOAD</ext-link>) provides a user-friendly web interface that allows users to query the database via multiple modules, mainly including ‘Search’, ‘Analysis’ and ‘Download’ (<xref rid="F3" ref-type="fig">Figure 3A</xref>). Several search/selection boxes are designed to select a specific cancer type or all cancer types. The corresponding cancer-specific synthetic lethal interactions will be presented via inputting the interested gene symbol or paired genes. Each gene pair also indicates the shared number by diverse cancers (<xref rid="F3" ref-type="fig">Figure 3B</xref>). For selected gene pair, further analysis can be presented, mainly including analysis of mutation, methylation, CNV and mRNA expression levels (<xref rid="F3" ref-type="fig">Figure 3C</xref>), and all of these visible results are also obtained on the Analysis page by inputting the interested genes.</p>
      <fig position="float" id="F3" fig-type="figure">
        <label>Figure 3.</label>
        <caption>
          <p>Overview of SLOAD database.</p>
        </caption>
        <graphic xlink:href="baac075f3" position="float"/>
        <attrib>(A) Main functions of SLOAD. (B) An example of searching modules in BRCA. All of synthetic lethal interactions in BRCA can be presented, and they are also detected in other cancer types. Amount indicates the genetic interactions shared by different cancer types. Further analysis is performed based on the selected gene pair of KRAS:CFDP1. (C) An example of further analysis of above-selected gene pair of KRAS:CFDP1, mainly including visible results of mutation level, methylation level, CNV level and mRNA expression level.</attrib>
      </fig>
      <p>Users can comprehensively browse cancer-specific synthetic lethal interactions and corresponding analysis results of different molecular levels. On the ‘Download’ page, users can obtain free access to the main data sets of cancer-specific synthetic lethal interactions in 31 cancers. The ‘Help’ page provides the detailed information about SLOAD. Furthermore, SLOAD welcomes feedback via the email address presented on the ‘Contact us’ page.</p>
    </sec>
  </sec>
  <sec id="s6">
    <title>Discussion and future directions</title>
    <p>As a strategy in cancer therapy with increasing interests and potential applications, SL has been widely concerned in cancer treatment, especially for recent clinical success (<xref rid="R8" ref-type="bibr">8</xref>). Given the importance of SL, many studies aim to comprehensively obtain experimentally verified and computationally predicted candidate synthetic lethal interactions that can provide potential targets for anticancer drugs (<xref rid="R18" ref-type="bibr">18–21</xref>, <xref rid="R30" ref-type="bibr">30</xref>, <xref rid="R32" ref-type="bibr">32</xref>, <xref rid="R42" ref-type="bibr">42–45</xref>), which can greatly promote the rapid development of cancer treatment based on the theory of SL (<xref rid="R46" ref-type="bibr">46</xref>). Although the concept of SL is an attractive therapeutic strategy, only PARPi has entered the clinic. One of the major hurdles is to identify clinically relevant and robust genetic interaction (<xref rid="R47" ref-type="bibr">47</xref>), and a critical challenge in personalized medicine is to identify mutation-specific therapies for a specific cancer type. Cancer-specific SL may be used as a promising cancer therapy, such as ATR and CHK1 inhibitors (<xref rid="R48" ref-type="bibr">48</xref>). It is urgent to provide cancer-specific synthetic lethal interactions, especially according to features of multi-omics data.</p>
    <p>Herein, based on reported candidate synthetic lethal interactions, we aim to further predict cancer-specific SL via integrating analysis of multi-omics data, mainly including DNA mutation, CNV, methylation and mRNA expression levels. Although DNA mutation is the main contributor in the prediction of synthetic lethal interactions, other molecular levels also contribute to obtaining cancer-specific genetic interactions, and integrating analysis of multi-omics data could provide more information and potential correlations among different molecular levels. According to obtained molecular features, cancer-specific gene pairs are predicted using decision tree and RF, and the latter has the better prediction performance. Then, SLOAD database is constructed according to these predicted results using RF, and the primary analysis is also provided in the database. Taken together, SLOAD provides cancer-specific synthetic lethal interactions via integrating multi-omics analysis and prediction and also presents the primary analysis at the different molecular levels. These cancer-specific synthetic lethal interactions may contribute to discovering novel targets for targeted therapy and promoting further application in precision medicine.</p>
    <p>In the future, we will continue to update SLOAD as follows: (i) we will perform an integrative analysis containing other molecular levels, especially the widely concerned non-coding RNAs (ncRNAs). As a class of important regulators in RNA regulatory network, diverse ncRNAs, mainly including small negative regulators, microRNAs and their multiple isoforms, long ncRNAs and circular RNAs, have been focused because of the flexible roles during perturbing gene expression, particularly the cross-talks among various RNAs and subsequent biological pathways. The complex interaction of ncRNAs will enrich our understanding of SL. (ii) More algorithms will be used to improve prediction accuracy, and the relevant data are simultaneously updated. (iii) We will update additional online functions according to user feedback to ensure its value as a user-friendly cancer-specific synthetic lethal interactions database. We expect that SLOAD can contribute to research on cancer treatment based on the theory of SL in precision medicine.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>baac075_Supp</label>
      <media xlink:href="baac075_supp.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <sec id="s7">
    <title>Supplementary data</title>
    <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are available at <italic toggle="yes">Database</italic> Online.</p>
  </sec>
  <sec id="s8">
    <title>Funding</title>
    <p>This work was supported by the National Natural Science Foundation of China (nos. 62171236 and 61771251), the key project of social development in Jiangsu Province (no. BE2022799), the key projects of Natural Science Research in Universities of Jiangsu Province (22KJA180006), the Qinglan Project in Jiangsu Province, Sponsored by NUPTSF (no. NY220041), the Open Research Fund of State Key Laboratory of Bioelectronics, Southeast University (SKLB2022-K03) and the Priority Academic Program Development of Jiangsu Higher Education Institution.</p>
  </sec>
  <sec id="s9">
    <title>Conflict of interest</title>
    <p>None declared.</p>
  </sec>
  <sec sec-type="data-availability" id="s10">
    <title>Data availability</title>
    <p>SLOAD (<ext-link xlink:href="http://www.tmliang.cn/SLOAD/" ext-link-type="uri">http://www.tmliang.cn/SLOAD/</ext-link>) is freely available to the public without registration or login requirements.</p>
  </sec>
  <sec id="s11">
    <title>Abbreviation lists of involved cancers in TCGA</title>
    <p>ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LIHC, liver hepatocellular carcinoma; LGG, brain Lower grade glioma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma.</p>
  </sec>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="R1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hartwell</surname><given-names>L.H.</given-names></string-name>, <string-name><surname>Szankasi</surname><given-names>P.</given-names></string-name>, <string-name><surname>Roberts</surname><given-names>C.J.</given-names></string-name></person-group><etal>et al.</etal> (<year>1997</year>) <article-title>Integrating genetic approaches into the discovery of anticancer drugs</article-title>. <source><italic toggle="yes">Science</italic></source>, <volume>278</volume>, <fpage>1064</fpage>–<lpage>1068</lpage>.doi: <pub-id pub-id-type="doi">10.1126/science.278.5340.1064</pub-id>.<pub-id pub-id-type="pmid">9353181</pub-id></mixed-citation>
    </ref>
    <ref id="R2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>B.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Yao</surname><given-names>Y.</given-names></string-name></person-group><etal>et al.</etal> (<year>2021</year>) <article-title>The tumor therapy landscape of synthetic lethality</article-title>. <source><italic toggle="yes">Nat. Commun.</italic></source>, <volume>12</volume>, <page-range>1275</page-range>.doi: <pub-id pub-id-type="doi">10.1038/s41467-021-21544-2</pub-id>.</mixed-citation>
    </ref>
    <ref id="R3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brody</surname><given-names>L.C.</given-names></string-name></person-group> (<year>2005</year>) <article-title>Treating cancer by targeting a weakness</article-title>. <source><italic toggle="yes">N. Engl. J. Med.</italic></source>, <volume>353</volume>, <fpage>949</fpage>–<lpage>950</lpage>.doi: <pub-id pub-id-type="doi">10.1056/NEJMcibr052331</pub-id>.<pub-id pub-id-type="pmid">16135843</pub-id></mixed-citation>
    </ref>
    <ref id="R4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ma</surname><given-names>H.</given-names></string-name>, <string-name><surname>Qi</surname><given-names>G.</given-names></string-name>, <string-name><surname>Han</surname><given-names>F.</given-names></string-name></person-group><etal>et al.</etal> (<year>2022</year>) <article-title>HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer</article-title>. <source><italic toggle="yes">Cell Death Dis</italic></source>, <volume>13</volume>, <page-range>263</page-range>.doi: <pub-id pub-id-type="doi">10.1038/s41419-022-04670-7</pub-id>.</mixed-citation>
    </ref>
    <ref id="R5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tewari</surname><given-names>K.S.</given-names></string-name>, <string-name><surname>Eskander</surname><given-names>R.N.</given-names></string-name> and <string-name><surname>Monk</surname><given-names>B.J.</given-names></string-name></person-group> (<year>2015</year>) <article-title>Development of olaparib for BRCA-deficient recurrent epithelial ovarian cancer</article-title>. <source><italic toggle="yes">Clin. Cancer Res.</italic></source>, <volume>21</volume>, <fpage>3829</fpage>–<lpage>3835</lpage>.doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-0088</pub-id>.<pub-id pub-id-type="pmid">26169965</pub-id></mixed-citation>
    </ref>
    <ref id="R6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Turk</surname><given-names>A.A.</given-names></string-name> and <string-name><surname>Wisinski</surname><given-names>K.B.</given-names></string-name></person-group> (<year>2018</year>) <article-title>PARP inhibitors in breast cancer: bringing synthetic lethality to the bedside</article-title>. <source><italic toggle="yes">Cancer</italic></source>, <volume>124</volume>, <fpage>2498</fpage>–<lpage>2506</lpage>.doi: <pub-id pub-id-type="doi">10.1002/cncr.31307</pub-id>.<pub-id pub-id-type="pmid">29660759</pub-id></mixed-citation>
    </ref>
    <ref id="R7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lord</surname><given-names>C.J.</given-names></string-name> and <string-name><surname>Ashworth</surname><given-names>A.</given-names></string-name></person-group> (<year>2017</year>) <article-title>PARP inhibitors: synthetic lethality in the clinic</article-title>. <source><italic toggle="yes">Science</italic></source>, <volume>355</volume>, <fpage>1152</fpage>–<lpage>1158</lpage>.doi: <pub-id pub-id-type="doi">10.1126/science.aam7344</pub-id>.<pub-id pub-id-type="pmid">28302823</pub-id></mixed-citation>
    </ref>
    <ref id="R8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lord</surname><given-names>C.J.</given-names></string-name>, <string-name><surname>Tutt</surname><given-names>A.N.</given-names></string-name> and <string-name><surname>Ashworth</surname><given-names>A.</given-names></string-name></person-group> (<year>2015</year>) <article-title>Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors</article-title>. <source><italic toggle="yes">Annu. Rev. Med.</italic></source>, <volume>66</volume>, <fpage>455</fpage>–<lpage>470</lpage>.doi: <pub-id pub-id-type="doi">10.1146/annurev-med-050913-022545</pub-id>.<pub-id pub-id-type="pmid">25341009</pub-id></mixed-citation>
    </ref>
    <ref id="R9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boss</surname><given-names>D.S.</given-names></string-name>, <string-name><surname>Beijnen</surname><given-names>J.H.</given-names></string-name> and <string-name><surname>Schellens</surname><given-names>J.H.</given-names></string-name></person-group> (<year>2010</year>) <article-title>Inducing synthetic lethality using PARP inhibitors</article-title>. <source><italic toggle="yes">Curr. Clin. Pharmacol.</italic></source>, <volume>5</volume>, <fpage>192</fpage>–<lpage>195</lpage>.doi: <pub-id pub-id-type="doi">10.2174/157488410791498798</pub-id>.<pub-id pub-id-type="pmid">20406170</pub-id></mixed-citation>
    </ref>
    <ref id="R10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ashworth</surname><given-names>A.</given-names></string-name>, <string-name><surname>Lord</surname><given-names>C.J.</given-names></string-name> and <string-name><surname>Reis-Filho</surname><given-names>J.S.</given-names></string-name></person-group> (<year>2011</year>) <article-title>Genetic interactions in cancer progression and treatment</article-title>. <source><italic toggle="yes">Cell</italic></source>, <volume>145</volume>, <fpage>30</fpage>–<lpage>38</lpage>.doi: <pub-id pub-id-type="doi">10.1016/j.cell.2011.03.020</pub-id>.<pub-id pub-id-type="pmid">21458666</pub-id></mixed-citation>
    </ref>
    <ref id="R11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Byrne</surname><given-names>A.B.</given-names></string-name>, <string-name><surname>Weirauch</surname><given-names>M.T.</given-names></string-name>, <string-name><surname>Wong</surname><given-names>V.</given-names></string-name></person-group><etal>et al.</etal> (<year>2007</year>) <article-title>A global analysis of genetic interactions in <italic toggle="yes">Caenorhabditis elegans</italic></article-title>. <source><italic toggle="yes">J. Biol.</italic></source>, <volume>6</volume>, <page-range>8</page-range>.doi: <pub-id pub-id-type="doi">10.1186/jbiol58</pub-id>.</mixed-citation>
    </ref>
    <ref id="R12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Costanzo</surname><given-names>M.</given-names></string-name>, <string-name><surname>Baryshnikova</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bellay</surname><given-names>J.</given-names></string-name></person-group><etal>et al.</etal> (<year>2010</year>) <article-title>The genetic landscape of a cell</article-title>. <source><italic toggle="yes">Science</italic></source>, <volume>327</volume>, <fpage>425</fpage>–<lpage>431</lpage>.doi: <pub-id pub-id-type="doi">10.1126/science.1180823</pub-id>.<pub-id pub-id-type="pmid">20093466</pub-id></mixed-citation>
    </ref>
    <ref id="R13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Typas</surname><given-names>A.</given-names></string-name>, <string-name><surname>Nichols</surname><given-names>R.J.</given-names></string-name>, <string-name><surname>Siegele</surname><given-names>D.A.</given-names></string-name></person-group><etal>et al.</etal> (<year>2008</year>) <article-title>High-throughput, quantitative analyses of genetic interactions in E</article-title>. <source><italic toggle="yes">Coli. Nat. Methods</italic></source>, <volume>5</volume>, <fpage>781</fpage>–<lpage>787</lpage>.doi: <pub-id pub-id-type="doi">10.1038/nmeth.1240</pub-id>.<pub-id pub-id-type="pmid">19160513</pub-id></mixed-citation>
    </ref>
    <ref id="R14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Costanzo</surname><given-names>M.</given-names></string-name>, <string-name><surname>VanderSluis</surname><given-names>B.</given-names></string-name>, <string-name><surname>Koch</surname><given-names>E.N.</given-names></string-name></person-group><etal>et al.</etal> (<year>2016</year>) <article-title>A global genetic interaction network maps a wiring diagram of cellular function</article-title>. <source><italic toggle="yes">Science</italic></source>, <volume>353</volume>, <page-range>aaf1420</page-range>.doi: <pub-id pub-id-type="doi">10.1126/science.aaf1420</pub-id>.</mixed-citation>
    </ref>
    <ref id="R15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bassik</surname><given-names>M.C.</given-names></string-name>, <string-name><surname>Kampmann</surname><given-names>M.</given-names></string-name>, <string-name><surname>Lebbink</surname><given-names>R.J.</given-names></string-name></person-group><etal>et al.</etal> (<year>2013</year>) <article-title>A systematic mammalian genetic interaction map reveals pathways underlying ricin susceptibility</article-title>. <source><italic toggle="yes">Cell</italic></source>, <volume>152</volume>, <fpage>909</fpage>–<lpage>922</lpage>.doi: <pub-id pub-id-type="doi">10.1016/j.cell.2013.01.030</pub-id>.<pub-id pub-id-type="pmid">23394947</pub-id></mixed-citation>
    </ref>
    <ref id="R16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brough</surname><given-names>R.</given-names></string-name>, <string-name><surname>Frankum</surname><given-names>J.R.</given-names></string-name>, <string-name><surname>Costa-Cabral</surname><given-names>S.</given-names></string-name></person-group><etal>et al.</etal> (<year>2011</year>) <article-title>Searching for synthetic lethality in cancer</article-title>. <source><italic toggle="yes">Curr. Opin. Genet. Dev.</italic></source>, <volume>21</volume>, <fpage>34</fpage>–<lpage>41</lpage>.doi: <pub-id pub-id-type="doi">10.1016/j.gde.2010.10.009</pub-id>.<pub-id pub-id-type="pmid">21255997</pub-id></mixed-citation>
    </ref>
    <ref id="R17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Laufer</surname><given-names>C.</given-names></string-name>, <string-name><surname>Fischer</surname><given-names>B.</given-names></string-name>, <string-name><surname>Billmann</surname><given-names>M.</given-names></string-name></person-group><etal>et al.</etal> (<year>2013</year>) <article-title>Mapping genetic interactions in human cancer cells with RNAi and multiparametric phenotyping</article-title>. <source><italic toggle="yes">Nat. Methods</italic></source>, <volume>10</volume>, <fpage>427</fpage>–<lpage>431</lpage>.doi: <pub-id pub-id-type="doi">10.1038/nmeth.2436</pub-id>.<pub-id pub-id-type="pmid">23563794</pub-id></mixed-citation>
    </ref>
    <ref id="R18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sinha</surname><given-names>S.</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>D.</given-names></string-name>, <string-name><surname>Chan</surname><given-names>S.</given-names></string-name></person-group><etal>et al.</etal> (<year>2017</year>) <article-title>Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data</article-title>. <source><italic toggle="yes">Nat. Commun.</italic></source>, <volume>8</volume>, <page-range>15580</page-range>.doi: <pub-id pub-id-type="doi">10.1038/ncomms15580</pub-id>.</mixed-citation>
    </ref>
    <ref id="R19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jerby-Arnon</surname><given-names>L.</given-names></string-name>, <string-name><surname>Pfetzer</surname><given-names>N.</given-names></string-name>, <string-name><surname>Waldman</surname><given-names>Y.Y.</given-names></string-name></person-group><etal>et al.</etal> (<year>2014</year>) <article-title>Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality</article-title>. <source><italic toggle="yes">Cell</italic></source>, <volume>158</volume>, <fpage>1199</fpage>–<lpage>1209</lpage>.doi: <pub-id pub-id-type="doi">10.1016/j.cell.2014.07.027</pub-id>.<pub-id pub-id-type="pmid">25171417</pub-id></mixed-citation>
    </ref>
    <ref id="R20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guo</surname><given-names>J.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>H.</given-names></string-name> and <string-name><surname>Zheng</surname><given-names>J.</given-names></string-name></person-group> (<year>2016</year>) <article-title>SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets</article-title>. <source><italic toggle="yes">Nucleic Acids Res.</italic></source>, <volume>44</volume>, <fpage>D1011</fpage>–<lpage>D1017</lpage>.doi: <pub-id pub-id-type="doi">10.1093/nar/gkv1108</pub-id>.<pub-id pub-id-type="pmid">26516187</pub-id></mixed-citation>
    </ref>
    <ref id="R21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>X.J.</given-names></string-name>, <string-name><surname>Mishra</surname><given-names>S.K.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>M.</given-names></string-name></person-group><etal>et al.</etal> (<year>2014</year>) <article-title>Syn-lethality: an integrative knowledge base of synthetic lethality towards discovery of selective anticancer therapies</article-title>. <source><italic toggle="yes">Biomed. Res. Int.</italic></source>, <volume>2014</volume>, <page-range>196034</page-range>.doi: <pub-id pub-id-type="doi">10.1155/2014/196034</pub-id>.</mixed-citation>
    </ref>
    <ref id="R22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Conde-Pueyo</surname><given-names>N.</given-names></string-name>, <string-name><surname>Munteanu</surname><given-names>A.</given-names></string-name>, <string-name><surname>Sole</surname><given-names>R.V.</given-names></string-name></person-group><etal>et al.</etal> (<year>2009</year>) <article-title>Human synthetic lethal inference as potential anti-cancer target gene detection</article-title>. <source><italic toggle="yes">BMC Syst Biol</italic></source>, <volume>3</volume>, <page-range>116</page-range>.doi: <pub-id pub-id-type="doi">10.1186/1752-0509-3-116</pub-id>.</mixed-citation>
    </ref>
    <ref id="R23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Folger</surname><given-names>O.</given-names></string-name>, <string-name><surname>Jerby</surname><given-names>L.</given-names></string-name>, <string-name><surname>Frezza</surname><given-names>C.</given-names></string-name></person-group><etal>et al.</etal> (<year>2011</year>) <article-title>Predicting selective drug targets in cancer through metabolic networks</article-title>. <source><italic toggle="yes">Mol. Syst. Biol.</italic></source>, <volume>7</volume>, <page-range>501</page-range>.doi: <pub-id pub-id-type="doi">10.1038/msb.2011.35</pub-id>.</mixed-citation>
    </ref>
    <ref id="R24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Frezza</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>L.</given-names></string-name>, <string-name><surname>Folger</surname><given-names>O.</given-names></string-name></person-group><etal>et al.</etal> (<year>2011</year>) <article-title>Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase</article-title>. <source><italic toggle="yes">Nature</italic></source>, <volume>477</volume>, <fpage>225</fpage>–<lpage>228</lpage>.doi: <pub-id pub-id-type="doi">10.1038/nature10363</pub-id>.<pub-id pub-id-type="pmid">21849978</pub-id></mixed-citation>
    </ref>
    <ref id="R25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Kensche</surname><given-names>P.R.</given-names></string-name>, <string-name><surname>Huynen</surname><given-names>M.A.</given-names></string-name></person-group><etal>et al.</etal> (<year>2013</year>) <article-title>Genome evolution predicts genetic interactions in protein complexes and reveals cancer drug targets</article-title>. <source><italic toggle="yes">Nat. Commun.</italic></source>, <volume>4</volume>, <page-range>2124</page-range>.doi: <pub-id pub-id-type="doi">10.1038/ncomms3124</pub-id>.</mixed-citation>
    </ref>
    <ref id="R26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>S.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>F.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.</given-names></string-name></person-group><etal>et al.</etal> (<year>2021</year>) <article-title>KG4SL: knowledge graph neural network for synthetic lethality prediction in human cancers</article-title>. <source><italic toggle="yes">Bioinformatics</italic></source>, <volume>37</volume>, <fpage>i418</fpage>–<lpage>i25</lpage>.doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/btab271</pub-id>.<pub-id pub-id-type="pmid">34252965</pub-id></mixed-citation>
    </ref>
    <ref id="R27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cai</surname><given-names>R.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>X.</given-names></string-name>, <string-name><surname>Fang</surname><given-names>Y.</given-names></string-name></person-group><etal>et al.</etal> (<year>2020</year>) <article-title>Dual-dropout graph convolutional network for predicting synthetic lethality in human cancers</article-title>. <source><italic toggle="yes">Bioinformatics</italic></source>, <volume>36</volume>, <fpage>4458</fpage>–<lpage>4465</lpage>.doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/btaa211</pub-id>.<pub-id pub-id-type="pmid">32221609</pub-id></mixed-citation>
    </ref>
    <ref id="R28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Long</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>M.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y.</given-names></string-name></person-group><etal>et al.</etal> (<year>2021</year>) <article-title>Graph contextualized attention network for predicting synthetic lethality in human cancers</article-title>. <source><italic toggle="yes">Bioinformatics</italic></source>, <volume>37</volume>, <fpage>2432</fpage>–<lpage>2440</lpage>.doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/btab110</pub-id>.</mixed-citation>
    </ref>
    <ref id="R29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>M.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>X.</given-names></string-name></person-group><etal>et al.</etal> (<year>2022</year>) <article-title>SynLethDB 2.0: a web-based knowledge graph database on synthetic lethality for novel anticancer drug discovery</article-title>. <source><italic toggle="yes">Database (Oxford)</italic></source>, <volume>2022</volume>, <page-range>baac030</page-range>.doi: <pub-id pub-id-type="doi">10.1093/database/baac030</pub-id>.</mixed-citation>
    </ref>
    <ref id="R30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname><given-names>J.S.</given-names></string-name>, <string-name><surname>Das</surname><given-names>A.</given-names></string-name>, <string-name><surname>Jerby-Arnon</surname><given-names>L.</given-names></string-name></person-group><etal>et al.</etal> (<year>2018</year>) <article-title>Harnessing synthetic lethality to predict the response to cancer treatment</article-title>. <source><italic toggle="yes">Nat. Commun.</italic></source>, <volume>9</volume>, <page-range>2546</page-range>.doi: <pub-id pub-id-type="doi">10.1038/s41467-018-04647-1</pub-id>.</mixed-citation>
    </ref>
    <ref id="R31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shen</surname><given-names>J.P.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>D.</given-names></string-name>, <string-name><surname>Sasik</surname><given-names>R.</given-names></string-name></person-group><etal>et al.</etal> (<year>2017</year>) <article-title>Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions</article-title>. <source><italic toggle="yes">Nat. Methods</italic></source>, <volume>14</volume>, <fpage>573</fpage>–<lpage>576</lpage>.doi: <pub-id pub-id-type="doi">10.1038/nmeth.4225</pub-id>.<pub-id pub-id-type="pmid">28319113</pub-id></mixed-citation>
    </ref>
    <ref id="R32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Srivas</surname><given-names>R.</given-names></string-name>, <string-name><surname>Shen</surname><given-names>J.P.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>C.C.</given-names></string-name></person-group><etal>et al.</etal> (<year>2016</year>) <article-title>A network of conserved synthetic lethal interactions for exploration of precision cancer therapy</article-title>. <source><italic toggle="yes">Mol. Cell</italic></source>, <volume>63</volume>, <fpage>514</fpage>–<lpage>525</lpage>.doi: <pub-id pub-id-type="doi">10.1016/j.molcel.2016.06.022</pub-id>.<pub-id pub-id-type="pmid">27453043</pub-id></mixed-citation>
    </ref>
    <ref id="R33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Colaprico</surname><given-names>A.</given-names></string-name>, <string-name><surname>Silva</surname><given-names>T.C.</given-names></string-name>, <string-name><surname>Olsen</surname><given-names>C.</given-names></string-name></person-group><etal>et al.</etal> (<year>2016</year>) <article-title>TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data</article-title>. <source><italic toggle="yes">Nucleic Acids Res.</italic></source>, <volume>44</volume>, <page-range>e71</page-range>.doi: <pub-id pub-id-type="doi">10.1093/nar/gkv1507</pub-id>.</mixed-citation>
    </ref>
    <ref id="R34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carithers</surname><given-names>L.J.</given-names></string-name> and <string-name><surname>Moore</surname><given-names>H.M.</given-names></string-name></person-group> (<year>2015</year>) <article-title>The genotype-tissue expression (GTEx) project</article-title>. <source><italic toggle="yes">Biopreserv Biobank</italic></source>, <volume>13</volume>, <fpage>307</fpage>–<lpage>308</lpage>.doi: <pub-id pub-id-type="doi">10.1089/bio.2015.29031.hmm</pub-id>.<pub-id pub-id-type="pmid">26484569</pub-id></mixed-citation>
    </ref>
    <ref id="R35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Consortium</surname><given-names>G.T.</given-names></string-name></person-group> (<year>2013</year>) <article-title>The genotype-tissue expression (GTEx) project</article-title>. <source><italic toggle="yes">Nat. Genet.</italic></source>, <volume>45</volume>, <fpage>580</fpage>–<lpage>585</lpage>.doi: <pub-id pub-id-type="doi">10.1038/ng.2653</pub-id>.<pub-id pub-id-type="pmid">23715323</pub-id></mixed-citation>
    </ref>
    <ref id="R36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ye</surname><given-names>H.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y.</given-names></string-name></person-group><etal>et al.</etal> (<year>2016</year>) <article-title>Ranking novel cancer driving synthetic lethal gene pairs using TCGA data</article-title>. <source><italic toggle="yes">Oncotarget</italic></source>, <volume>7</volume>, <fpage>55352</fpage>–<lpage>55367</lpage>.doi: <pub-id pub-id-type="doi">10.18632/oncotarget.10536</pub-id>.<pub-id pub-id-type="pmid">27438146</pub-id></mixed-citation>
    </ref>
    <ref id="R37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Robinson</surname><given-names>M.D.</given-names></string-name>, <string-name><surname>McCarthy</surname><given-names>D.J.</given-names></string-name> and <string-name><surname>Smyth</surname><given-names>G.K.</given-names></string-name></person-group> (<year>2010</year>) <article-title>edgeR: a Bioconductor package for differential expression analysis of digital gene expression data</article-title>. <source><italic toggle="yes">Bioinformatics</italic></source>, <volume>26</volume>, <fpage>139</fpage>–<lpage>140</lpage>.doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/btp616</pub-id>.<pub-id pub-id-type="pmid">19910308</pub-id></mixed-citation>
    </ref>
    <ref id="R38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liaw</surname><given-names>A.</given-names></string-name> and <string-name><surname>Wiener</surname><given-names>M.</given-names></string-name></person-group> (<year>2001</year>) <article-title>Classification and regression by randomForest</article-title>. <source><italic toggle="yes">Forest</italic></source>, <volume>2</volume>, <fpage>18</fpage>–<lpage>22</lpage>.</mixed-citation>
    </ref>
    <ref id="R39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scholl</surname><given-names>C.</given-names></string-name>, <string-name><surname>Frohling</surname><given-names>S.</given-names></string-name>, <string-name><surname>Dunn</surname><given-names>I.F.</given-names></string-name></person-group><etal>et al.</etal> (<year>2009</year>) <article-title>Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells</article-title>. <source><italic toggle="yes">Cell</italic></source>, <volume>137</volume>, <fpage>821</fpage>–<lpage>834</lpage>.doi: <pub-id pub-id-type="doi">10.1016/j.cell.2009.03.017</pub-id>.<pub-id pub-id-type="pmid">19490892</pub-id></mixed-citation>
    </ref>
    <ref id="R40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Steckel</surname><given-names>M.</given-names></string-name>, <string-name><surname>Molina-Arcas</surname><given-names>M.</given-names></string-name>, <string-name><surname>Weigelt</surname><given-names>B.</given-names></string-name></person-group><etal>et al.</etal> (<year>2012</year>) <article-title>Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies</article-title>. <source><italic toggle="yes">Cell Res.</italic></source>, <volume>22</volume>, <fpage>1227</fpage>–<lpage>1245</lpage>.doi: <pub-id pub-id-type="doi">10.1038/cr.2012.82</pub-id>.<pub-id pub-id-type="pmid">22613949</pub-id></mixed-citation>
    </ref>
    <ref id="R41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mao</surname><given-names>C.Q.</given-names></string-name>, <string-name><surname>Xiong</surname><given-names>M.H.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y.</given-names></string-name></person-group><etal>et al.</etal> (<year>2014</year>) <article-title>Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery</article-title>. <source><italic toggle="yes">Mol. Ther.</italic></source>, <volume>22</volume>, <fpage>964</fpage>–<lpage>973</lpage>.doi: <pub-id pub-id-type="doi">10.1038/mt.2014.18</pub-id>.<pub-id pub-id-type="pmid">24496383</pub-id></mixed-citation>
    </ref>
    <ref id="R42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Whitehurst</surname><given-names>A.W.</given-names></string-name>, <string-name><surname>Bodemann</surname><given-names>B.O.</given-names></string-name>, <string-name><surname>Cardenas</surname><given-names>J.</given-names></string-name></person-group><etal>et al.</etal> (<year>2007</year>) <article-title>Synthetic lethal screen identification of chemosensitizer loci in cancer cells</article-title>. <source><italic toggle="yes">Nature</italic></source>, <volume>446</volume>, <fpage>815</fpage>–<lpage>819</lpage>.doi: <pub-id pub-id-type="doi">10.1038/nature05697</pub-id>.<pub-id pub-id-type="pmid">17429401</pub-id></mixed-citation>
    </ref>
    <ref id="R43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bommi-Reddy</surname><given-names>A.</given-names></string-name>, <string-name><surname>Almeciga</surname><given-names>I.</given-names></string-name>, <string-name><surname>Sawyer</surname><given-names>J.</given-names></string-name></person-group><etal>et al.</etal> (<year>2008</year>) <article-title>Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen</article-title>. <source><italic toggle="yes">Proc. Natl. Acad. Sci. U.S.A.</italic></source>, <volume>105</volume>, <fpage>16484</fpage>–<lpage>16489</lpage>.doi: <pub-id pub-id-type="doi">10.1073/pnas.0806574105</pub-id>.<pub-id pub-id-type="pmid">18948595</pub-id></mixed-citation>
    </ref>
    <ref id="R44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Luo</surname><given-names>J.</given-names></string-name>, <string-name><surname>Emanuele</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Li</surname><given-names>D.</given-names></string-name></person-group><etal>et al.</etal> (<year>2009</year>) <article-title>A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene</article-title>. <source><italic toggle="yes">Cell</italic></source>, <volume>137</volume>, <fpage>835</fpage>–<lpage>848</lpage>.doi: <pub-id pub-id-type="doi">10.1016/j.cell.2009.05.006</pub-id>.<pub-id pub-id-type="pmid">19490893</pub-id></mixed-citation>
    </ref>
    <ref id="R45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vizeacoumar</surname><given-names>F.J.</given-names></string-name>, <string-name><surname>Arnold</surname><given-names>R.</given-names></string-name>, <string-name><surname>Vizeacoumar</surname><given-names>F.S.</given-names></string-name></person-group><etal>et al.</etal> (<year>2013</year>) <article-title>A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities</article-title>. <source><italic toggle="yes">Mol. Syst. Biol.</italic></source>, <volume>9</volume>, <page-range>696</page-range>.doi: <pub-id pub-id-type="doi">10.1038/msb.2013.54</pub-id>.</mixed-citation>
    </ref>
    <ref id="R46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Han</surname><given-names>J.</given-names></string-name></person-group><etal>et al.</etal> (<year>2022</year>) <article-title>Computational methods, databases and tools for synthetic lethality prediction</article-title>. <source><italic toggle="yes">Brief. Bioinformatics</italic></source>, <volume>23</volume>, <page-range>bbac106</page-range>.doi: <pub-id pub-id-type="doi">10.1093/bib/bbac106</pub-id>.</mixed-citation>
    </ref>
    <ref id="R47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>O’Neil</surname><given-names>N.J.</given-names></string-name>, <string-name><surname>Bailey</surname><given-names>M.L.</given-names></string-name> and <string-name><surname>Hieter</surname><given-names>P.</given-names></string-name></person-group> (<year>2017</year>) <article-title>Synthetic lethality and cancer</article-title>. <source><italic toggle="yes">Nat. Rev. Genet.</italic></source>, <volume>18</volume>, <fpage>613</fpage>–<lpage>623</lpage>.doi: <pub-id pub-id-type="doi">10.1038/nrg.2017.47</pub-id>.<pub-id pub-id-type="pmid">28649135</pub-id></mixed-citation>
    </ref>
    <ref id="R48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sanjiv</surname><given-names>K.</given-names></string-name>, <string-name><surname>Hagenkort</surname><given-names>A.</given-names></string-name>, <string-name><surname>Calderon-Montano</surname><given-names>J.M.</given-names></string-name></person-group><etal>et al.</etal> (<year>2016</year>) <article-title>Cancer-specific synthetic lethality between ATR and CHK1 kinase activities</article-title>. <source><italic toggle="yes">Cell Rep</italic></source>, <volume>14</volume>, <fpage>298</fpage>–<lpage>309</lpage>.doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2015.12.032</pub-id>.<pub-id pub-id-type="pmid">26748709</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
